Par Gets PTAB Review Of Afinitor Patent
Days after rejecting a challenge from Roxane Laboratories to a patent related to Novartis' blockbuster cancer drug Afinitor, the Patent Trial and Appeal Board agreed recently to review the patent based...To view the full article, register now.
Already a subscriber? Click here to view full article